Generics Erosion Patterns in the U.S. Market

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Methodology
• Factors Infl uencing Generics Erosion
• Exceptions to Traditional Generics Erosion Patterns
• Patterns of Generics Erosion by Formulation
  • Oral Solids
    • Group 1
    • Group 2
    • Group 3
  • Oral Liquids and Other Formulations (Nasal, Ophthalmic Liquids, Patches/Discs)
  • Injectables
• Other Findings
  • Comparison of Average Oral Solid Generics Erosion
  • Market Infl uence of Generics Manufacturers
  • Price As a Factor
• Will These Patterns Continue?

Tables

• 1. Drugs and Formualtions Examined in this Report
• 2. Defi nitions and Parameters of Drug Groupings in this Report

Figures

• 1. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 1
• 2. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 2
• 3. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 3
• 4. Generics Erosion for Selected Products, 2002-2006: Oral Liquids
• 5. Generics Erosion for Selected Products, 2002-2006: Other Formulations
• 6. Comparison of Average Generics Erosion (by Formulation) for Five Drugs
• 7. Generics Erosion for Selected Products, 2002-2006: Injectables/IVs
• 8. Average Generics Erosion Rates of Oral Solids, 2002-2006
• 9. Estimated Average Number of Generics Competitors by Formulation
• 10. The Effect of Generics Manufacturers on Brand Market Share Volume
• 11. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Zithromax
• 12. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Lotensin
• 13. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Celexa